Davion Healthcare Plc Welcomes New CFO and Independent Director to Board
Davion Healthcare Plc Welcomes New CFO and Independent Director to Board
On December 2, 2025, Davion Healthcare Plc, a prominent medical technology firm focused on developing non-invasive home testing solutions, announced the strategic appointments of Mr. Andreas Ttofi as Chief Financial Officer (CFO) and Mr. Jan Dulman, CPA, as an Independent Non-Executive Director and Chair of the Audit Committee. These appointments are effective immediately and mark a significant step for the company as it gears up for its listing on the NASDAQ and aims for global expansion.
Strengthening Financial Leadership
Andreas Ttofi - Chief Financial Officer
Andreas Ttofi joins Davion with a wealth of experience in finance and a solid track record of professional excellence. A member of the Association of Chartered Certified Accountants (ACCA), Ttofi has gathered over ten years of extensive experience in audit, financial reporting, and operational finance. His tenure has seen him advising a variety of corporate and private clients across different sectors, earning him a reputation for high accuracy and compliance with regulatory standards. His areas of expertise include statutory accounts preparation, audit oversight, capital gains tax analysis, payroll governance, and managing corporate funds. His disciplined and ethical approach to financial stewardship will support Davion’s ambitious growth strategy moving forward.
Jan Dulman - Independent Non-Executive Director
Mr. Jan Dulman brings immense value to Davion as a seasoned CPA with a wealth of experience as both an CFO and audit professional. His career commenced in Stamford, Connecticut, where he honed his foundational skills in auditing and financial management. He later ascended to the role of Controller and CFO for a public mining exploration company. Furthermore, Dulman founded and merged his CPA partnership into a national operation where he made significant contributions as the head of the Attest Services division, guiding the firm's significant SEC and Broker-Dealer practices. Notably, he has managed major regulatory filings, including overseeing one of the largest Regulation A registrations in U.S. history, all of which equip him with the knowledge necessary for financial governance and comprehensive audit oversight at Davion.
Chairman’s Statement
In a statement regarding the new appointments, Sir Eric Peacock, Chairman of Davion Healthcare, expressed his enthusiasm about the additions to the team, highlighting, "Our Board is delighted to welcome Andreas and Jan at this pivotal stage for the Company. They bring invaluable expertise in financial discipline and SEC compliance. Their combined leadership significantly enhances our Board as we aim for our imminent NASDAQ listing and embark on greater growth initiatives."
Innovative Products and Vision for the Future
Davion Healthcare is at the forefront of medical technology innovation, dedicated to improving accessibility to early detection tools for various medical anomalies, including cancer. Their flagship product, BreastCheck, is a non-invasive, FDA-registered at-home test that utilizes a thermosensitive patch and a mobile app to help identify potential health issues at an early stage without requiring a clinical visit. The commercial launch of BreastCheck is anticipated by the end of the first half of 2026.
In addition to BreastCheck, the company is working on diversifying its product line, which includes:
- - FootFlow: A non-invasive foot temperature monitoring tool aimed at early detection of peripheral artery disease (PAD) and diabetes.
- - Testic: An at-home test for monitoring testicular health.
- - ThermaDerm: A clinician-centric thermal pad for detecting skin anomalies.
Their mission revolves around enhancing access to early detection technologies, easing pressures on healthcare systems, and enabling timely interventions through affordable and accessible medical solutions.
Conclusion
Davion Healthcare Plc stands at a promising juncture with their new leadership team. The combination of expertise brought by Andreas Ttofi and Jan Dulman is expected to propel the company forward as it prepares for significant milestones, such as their NASDAQ listing, while continuing to push the boundaries of medical technology for a healthier future. As the company embarks on this exciting journey, stakeholders can expect a focus on innovation and a commitment to improving health outcomes globally.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.